LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of “Moderate Buy” from Brokerages

LB Pharmaceuticals Inc (NASDAQ:LBRX) has been assigned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $45.1250.

A number of brokerages have recently issued reports on LBRX. BMO Capital Markets assumed coverage on LB Pharmaceuticals in a research report on Monday, July 20th. They set an “outperform” rating and a $46.00 price target for the company. Wolfe Research initiated coverage on shares of LB Pharmaceuticals in a research note on Tuesday, July 7th. They issued an “outperform” rating and a $45.00 target price on the stock. Craig Hallum started coverage on shares of LB Pharmaceuticals in a research report on Friday, April 10th. They set a “buy” rating and a $36.00 target price for the company. Roth Capital reissued a “buy” rating and issued a $37.00 price target on shares of LB Pharmaceuticals in a research note on Sunday, May 17th. Finally, Piper Sandler reissued an “overweight” rating and issued a $78.00 price target on shares of LB Pharmaceuticals in a report on Monday.

Institutional Investors Weigh In On LB Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in LBRX. Jefferies Financial Group Inc. bought a new stake in LB Pharmaceuticals during the third quarter worth about $207,000. Landscape Capital Management L.L.C. bought a new position in shares of LB Pharmaceuticals during the 3rd quarter valued at about $168,000. Squarepoint Ops LLC bought a new position in shares of LB Pharmaceuticals during the 3rd quarter valued at about $329,000. Two Sigma Investments LP purchased a new position in shares of LB Pharmaceuticals during the 3rd quarter valued at about $213,000. Finally, Balyasny Asset Management L.P. bought a new stake in LB Pharmaceuticals in the 3rd quarter worth approximately $15,289,000.

Key Stories Impacting LB Pharmaceuticals

Here are the key news stories impacting LB Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $3.51 from $3.61 and its FY2027 estimate to a loss of $4.87 from $5.30. Quarterly estimates were also improved, including Q3 2026 to a loss of $0.95, Q4 2026 to $1.07, and each quarter of 2027. The revisions indicate better anticipated earnings performance, although LB Pharmaceuticals is still expected to remain unprofitable. HC Wainwright Reaffirms Buy Rating for LB Pharmaceuticals
• Neutral Sentiment: The $45 price target is broadly in line with the stock’s recent trading level, limiting the immediate implied upside from HC Wainwright’s recommendation. The company also continues to carry a negative earnings outlook, with consensus calling for a full-year loss of $3.58 per share.

LB Pharmaceuticals Stock Performance

Shares of LBRX stock opened at $45.03 on Thursday. The company has a market capitalization of $1.29 billion and a PE ratio of -26.03. LB Pharmaceuticals has a 52-week low of $13.36 and a 52-week high of $46.01. The business’s fifty day moving average is $32.44 and its 200 day moving average is $28.21.

LB Pharmaceuticals (NASDAQ:LBRX) last posted its earnings results on Tuesday, May 12th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, sell-side analysts forecast that LB Pharmaceuticals will post -3.55 EPS for the current fiscal year.

About LB Pharmaceuticals

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.